We are proud to announce that the certification of our nuclear medicine institution as a  Theranostics Centre of Excellence has been renewed for 2025 — and extended to include therapies with Terbium-161, currently the only institution offering it in Austria.

VIOLET Study – First Results Coinciding with the launch of the therapy at our center, the early results of the VIOLET study, the first-in-human trial of ¹⁶¹Tb-PSMA, are being published. And they are highly promising! No dose-limiting toxicities were observed across six treatment cycles (up to 7.4 GBq) in 30 patients. Encouraged by these results,…

Primo Medico Specialist Talk, the Specialists’ Podcast with Susanne Amrhein — “Medicine for the Ears”

The FDA has expanded the indication for ¹⁷⁷Lu-PSMA-617 (Pluvicto®), now approving its use before chemotherapy in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Eligible patients must have: PSMA PET-positive disease disease progression on androgen deprivation therapy (ADT) and one androgen receptor pathway inhibitor (ARPI) The decision is based on positive results from the phase…

We are pleased to announce our collaboration with the Croatian Health Insurance Fund (Hrvatski Zavod Za Zdravstvene Osiguranje), which now enables its patients to access Pluvicto® (PSMA radioligand therapy) within the approved indication in an outpatient setting! This is a great step for patient care—but just a small step for the patient, as outpatient therapy…

Refuting Oncologist’s Doubts About Radioligand Therapy: A Case for Confidence As ¹⁷⁷Lu-PSMA therapy gains attention for its role in treating metastatic castration-resistant prostate cancer (mCRPC), some oncologists remain hesitant to fully embrace it. Their concerns, while understandable, are often based on regulatory, safety, and patient selection uncertainties. However, a growing body of evidence and clinical…

We are proud to announce that we have been accredited as a Theranostics Center of Excellence by the European Association of Nuclear Medicine (EANM). Currently, our facility is the only one in Austria to be awarded the EARL certificate.

Here is a testimonial of one of our patients: “I would like to announce hereby to the world that the small private clinic Minute Medical in Vienna led by Professor Markus Hartenbach, an expert in Nuclear Medicine, is nothing but a giant in helping people in need of medical attention, proving the success of day-to-day…

You can listen to this article.   The European Association of Nuclear Medicine (EANM) hosted its annual conference, EANM24, from October 19-22, 2024, in Hamburg, Germany. EANM conferences are known for showcasing advancements in nuclear medicine, which can be broadly categorized into key areas: New Targets: Identification of novel proteins and enzymes in different cancers…

The results of the UpFrontPSMA trial are in, unveiled during the ESMO 2024 in Barcelona, and they are truly encouraging for the future of prostate cancer treatment. 177Lu-PSMA radioligand therapy (RLT) has taken a significant leap forward in the treatment protocol, now positioning ahead of docetaxel chemotherapy. Initially introduced after the VISION trial as a…

Download PDF here “Thrombotic microangiopathy (TMA) is rare and its cancer-related subset even more so. TMA triggered by drugs is the most common within this group, including classic chemotherapy and the latest targeted therapies. The neoplastic disease itself and hematopoietic stem-cell transplantation could also be potential triggers.”[1] “Drug-induced nephrotoxicity tends to occur more frequently in…

Interview with Priv.-Doz. Dr. Wolfgang Wadsak in Onko News Austria, No. 7-8, October 2023 (German) With PSMA radioligand therapy, nuclear medicine offers a promising, non-invasive procedure for diagnosing and treating prostate cancer, that has hardly any side effects and a life-prolonging effect even in the final stages while maintaining a good quality of life. 2023_11_07_Onko_News_EANM

Joint EANM procedure guideline / SNMMI procedure standard for prostate cancer imaging 2.0 EANM and SNMMI have updated their joint PSMA PET/CT procedure guideline for prostate cancer imaging with the most recent information. “This guideline supports physicians in recommending, acquiring, interpreting and reporting the results of PSMA-ligand PET/CT for initial diagnosis, staging and restaging of…

Video: Nuclear imaging 68Ga-DOTATATE and PRRT 177Lu-DOTATATE explained (English) NET Patient Education Conference of NET Research Foundation on Theranostics (PRRT), Stanford, US, March 2017

New phase III 177Lu-PSMA-617 trial in mCRPC patients at the stage of antihormonal therapy

New phase III 177Lu-PSMA-617 trial in mCRPC patients who have not undergone chemotherapy.

ASCO 2021: Phase III Study of Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)

The New England Journal of Medicine: “Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer” 

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors  Informationen zu Lutathera